Share

January 30, 2018; 90 (5) Editorial

Caffeine and Parkinson disease

A possible diagnostic and pathogenic breakthrough

David G. Munoz, Shinsuke Fujioka
First published January 3, 2018, DOI: https://doi.org/10.1212/WNL.0000000000004898
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
354

Share

Article Information

vol. 90 no. 5 205-206
DOI: 
https://doi.org/10.1212/WNL.0000000000004898
PubMed: 
29298853
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published January 3, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. David G. Munoz, MD, FRCPC and
    2. Shinsuke Fujioka, MD
  1. David G. Munoz, MD, FRCPC and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Physicians? Services Incorporated Foundation Canada 2. Michael J. Fox Foundation for Parkinson?s Research. MJFF Grant Reference #9035.01. 3. Radiological Society of North America. RSCH1516. 4.Michael J. Fox Foundation for Parkinson?s Research. MJFF Grant Reference #9035.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Shinsuke Fujioka, MD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Parkinsonism and Related Disorders, an editorial board member, 2015-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Laboratory Medicine and Pathobiology (D.G.M.), University of Toronto, Canada; and Department of Neurology (S.F.), Fukuoka University, Japan.
  1. Correspondence
    Dr. Munoz munozd{at}smh.ca
View Full Text

Article usage

Article usage: January 2018 to February 2023

AbstractFullPdfSource
Jan 2018210679109Highwire
Feb 20187794946Highwire
Mar 20186831233Highwire
Apr 2018679811Highwire
May 2018629310Highwire
Jun 201851648Highwire
Jul 201846154Highwire
Aug 201850249Highwire
Sep 2018589310Highwire
Oct 2018756715Highwire
Nov 2018948310Highwire
Dec 2018886211Highwire
Jan 2019610616Highwire
Feb 201970140Highwire
Mar 20191191213Highwire
Apr 2019601286Highwire
May 201956341Highwire
Jun 201942473Highwire
Jul 2019388172Highwire
Aug 201946862Highwire
Sep 2019446161Highwire
Oct 2019564163Highwire
Nov 201956974Highwire
Dec 201950352Highwire
Jan 202057472Highwire
Feb 2020830102Highwire
Mar 202062044Highwire
Apr 202053532Highwire
May 202061823Highwire
Jun 202039710Highwire
Jul 202038900Highwire
Aug 202031571Highwire
Sep 202048252Highwire
Oct 202048343Highwire
Nov 202054861Highwire
Dec 202066810Highwire
Jan 202146201Highwire
Feb 202158621Highwire
Mar 202148011Highwire
Apr 202141220Highwire
May 202140520Highwire
Jun 202145421Highwire
Jul 202129900Highwire
Aug 202132300Highwire
Sep 202124510Highwire
Oct 202139421Highwire
Nov 202139601Highwire
Dec 202135611Highwire
Jan 2022100910Highwire
Feb 2022104360Highwire
Mar 202283941Highwire
Apr 202229531Highwire
May 202226610Highwire
Jun 202221700Highwire
Jul 202221311Highwire
Aug 202225700Highwire
Sep 202230811Highwire
Oct 202229511Highwire
Nov 202225321Highwire
Dec 202224400Highwire
Jan 202322121Highwire
Feb 202329211Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles